Close

Ardea (RDEA) Initiates Potenital Gout Treatment Lesinurad Phase 3

December 19, 2011 8:01 AM EST
Ardea Biosciences, Inc. (Nasdaq: RDEA) has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company's lead product candidate for the chronic treatment of gout. The lesinurad Phase 3 development program is expected to involve approximately 2,000 gout patients at sites around the world. The remaining Phase 3 studies in the program are expected to begin shortly.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA